相关临床试验
1413
169 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
1969
终止
92
6.5%
招募中
213
15.1%
暂停
2
0.1%
撤回
126
8.9%
进行中（未招募）
80
5.7%
Unknown
3
0.2%
已完成
808
57.2%
Enrolling By Invitation
6
0.4%
尚未招募
83
5.9%
- Two University of Alabama at Birmingham PhD candidates are conducting research aimed at advancing Targeted Alpha Therapy, an emerging approach to cancer treatment that uses radioactive materials to target cancer cells. - One researcher focuses on astatine-211, a radioactive isotope that releases powerful alpha particles over a very short distance, potentially destroying cancer cells while limiting damage to healthy tissue. - The second researcher is developing nanomaterials that can accommodate multiple metal ions, enabling combined therapeutic alpha radiation and diagnostic imaging in a single nanoparticle. - The work is supported by U.S. Department of Energy grants, including the Horizon-broadening Isotope Production Pipeline Opportunities program and the DOE Established Program to Stimulate Competitive Research.
- A study published in Cell Reports Medicine found that indigo light (419–446 nm) completely prevented myopia development in tree shrews, an animal model with human-like eyes. - The research suggests modern white LED lighting lacks indigo wavelengths, which may contribute to the global "myopia boom" affecting children and adolescents. - Researchers developed a new metric, the μ-opic, to quantify how effectively different light wavelengths protect against myopia. - A UAB startup, Electric Indigo, is developing eyewear with LEDs that emit indigo light, with future clinical studies planned in daycare settings.
- The Heersink School of Medicine announced eight inaugural projects selected for its new Team Science Grant Program, each funded up to $150,000 per year for up to two years. - The program fosters interdisciplinary collaboration across Heersink and UAB, aligning with strategic research focus areas including D-TECH, HEAL, I-4ward, Brain Health and Disease Across the Lifespan, and Implementation Science. - Awarded projects span chronic kidney disease, substance use disorders, opioid addiction, infectious disease, epilepsy, mental health, arthritis, and neurodegenerative disease. - The initiative aims to seed collaborations that can grow into large-scale, externally funded research initiatives, including multi-investigator NIH grants and center grants.
- NuVasc, a University of Alabama at Birmingham startup, is developing a liquid biopsy that detects the genetic driver mutations underlying brain arteriovenous malformations during routine endovascular procedures. - Three-quarters of sporadic bAVMs are driven by activating mutations in the KRAS or BRAF genes, alterations already established as drug targets in cancer. - The diagnostic approach was developed by Andrew T. Hale, M.D., Ph.D., in collaboration with Kristopher T. Kahle, M.D., Ph.D., of Massachusetts General Hospital, and is exclusively licensed to NuVasc. - The company is in an early translational stage, aiming to connect molecular diagnosis directly to targeted therapy for a disease with high unmet need and no targeted options today.
- Women in socially vulnerable neighborhoods face a 20% higher risk of death after an ovarian cancer diagnosis compared to those in less vulnerable areas, according to a Pitt-led study published in JAMA Network Open. - Black women experience a 45% higher risk of death than white women, and the combination of Black race and high neighborhood vulnerability carries a greater risk than either factor alone. - The study analyzed data from 2,544 women (509 Black, 2,035 white) treated at the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, linking residential census tracts to the CDC's Social Vulnerability Index. - Researchers recommend health systems incorporate neighborhood-level measures into cancer care planning to identify at-risk patients and connect them with support services such as patient navigation and transportation assistance.
- The NIH-funded Population Genomic Screening Network will pilot genomic screening for actionable genetic conditions in primary care settings across six U.S. clinical sites. - Baylor College of Medicine will serve as the sequencing center with $9.9 million over five years, while UAB receives $4.9 million to enroll approximately 5,000 participants. - Screening will target CDC Tier 1 conditions including hereditary breast and ovarian cancer, Lynch syndrome, and familial hypercholesterolemia, plus additional conditions like transthyretin amyloidosis and hypertrophic cardiomyopathy. - The initiative aims to shift from reactive care to proactive prevention by returning genomic results to patients and providers with evidence-based follow-up recommendations.
- The CDC issued a clinician alert after rabies-related inquiries rose 17% in July and August versus the same period last year, with vaccine use up 33% and immune globulin up 76%. - The alert followed the euthanasia of four rabid baby goats at a North Carolina petting zoo that exposed people to the virus, an event experts say may explain the entire increase. - A separate CMAJ report documented Ontario's first fatal human rabies case since 1967 in an 11-year-old boy exposed to a bat without visible bite or scratch marks. - Authors of the case report stress that any direct human contact with a bat warrants post-exposure prophylaxis, which is highly effective if given before symptoms develop.
- A 2017 JAMA Dermatology study found that 14 lung cancer patients treated with immunotherapy experienced re-pigmentation of their gray hair as an unexpected side effect. - Researchers, including Melissa Harris, Ph.D. at the University of Alabama at Birmingham, are investigating immunotherapy to reactivate melanocyte stem cells and restore hair pigment. - Gray hair results from melanocytes no longer migrating to the hair follicle base to produce melanin after repeated hair cycles, with stress also contributing via norepinephrine release. - Current anti-gray serums and supplements lack definitive scientific evidence for reversing gray hair, and no FDA-approved treatments exist for this purpose.
- The Gorrie family has contributed $10 million to expand Alzheimer's disease research, education, patient care, and community outreach at the UAB Marnix E. Heersink School of Medicine. - The gift establishes the Frances Gorrie Alzheimer's Disease Center, which will accelerate clinical trials, train more cognitive neurology specialists, and expand community care access across Alabama. - More than 7 million Americans live with Alzheimer's disease, a figure projected to nearly double by 2050, with Alabama recording the sixth-highest rate of Alzheimer's-related deaths in 2024. - New anti-amyloid therapies have recently been shown to slow Alzheimer's disease progression by as much as 30 percent, underscoring the urgency of expanding translational research.
- The University of Alabama at Birmingham ranked No. 42 and the Medical University of South Carolina ranked No. 44 out of 303 leading U.S. biomedical research institutions in the inaugural 2026 Cure Innovation Index. - The Cure Innovation Index is the first national, data-driven platform evaluating how effectively institutions convert scientific discovery into therapies, companies, and measurable health outcomes across 25 indicators. - UAB demonstrated particular strength in market translation and entrepreneurial readiness, while MUSC earned "Excellent" ratings in cutting-edge science, facilities and equipment, faculty engagement, and industry connections. - Both institutions have made significant investments in innovation infrastructure, including startup incubators, venture funds, and technology transfer programs to accelerate the path from discovery to patient impact.
